marketcaparena
Search

    MEDP

    Medpace Holdings, Inc.

    Company overview

    Market capitalization
    $17.19B
    Employees
    6,300
    Latest publication
    2026-09-29
    About Medpace Holdings, Inc.

    Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue707,331,000USD706,604,000USD708,450,000USD659,903,000USD603,311,000USD558,570,000USD536,589,000USD533,317,000USD
    Cost Of Revenue512,404,000USD510,278,000USD503,134,000USD462,964,000USD423,298,000USD380,220,000USD358,272,000USD364,309,000USD
    Gross Profit194,927,000USD196,326,000USD205,316,000USD196,939,000USD180,013,000USD178,350,000USD178,317,000USD169,008,000USD
    Selling General Administrative48,103,000USD47,917,000USD44,916,000USD48,082,000USD46,664,000USD57,897,000USD43,933,000USD49,217,000USD
    Total Operating Expenses48,103,000USD54,823,000USD52,047,000USD55,131,000USD53,678,000USD64,827,000USD52,939,000USD56,735,000USD
    Operating Income146,824,000USD141,503,000USD153,269,000USD141,808,000USD126,335,000USD113,523,000USD125,378,000USD112,273,000USD
    Total Other Income Expense Net4,839,000USD6,088,000USD3,564,000USD1,028,000USD-1,797,000USD4,647,000USD8,504,000USD6,503,000USD
    Income Before Tax151,663,000USD147,591,000USD156,833,000USD142,836,000USD124,538,000USD118,170,000USD133,882,000USD118,776,000USD
    Income Tax Expense30,301,000USD23,721,000USD21,700,000USD31,701,000USD34,278,000USD3,575,000USD16,864,000USD22,350,000USD
    Net Income121,362,000USD123,870,000USD135,133,000USD111,135,000USD90,260,000USD114,595,000USD117,018,000USD96,426,000USD
    Unclassified Operating Expenses—6,906,000USD7,131,000USD7,049,000USD7,014,000USD6,930,000USD7,506,000USD7,518,000USD
    Net Interest Income—5,117,000USD3,722,000USD1,517,000USD1,078,000USD6,463,000USD7,883,000USD7,528,000USD
    Tax Provision—23,721,000USD21,700,000USD31,701,000USD34,278,000USD3,575,000USD16,864,000USD22,350,000USD
    Net Income From Continuing Ops—123,870,000USD135,133,000USD111,135,000USD90,260,000USD114,595,000USD117,018,000USD96,426,000USD
    Ebit—147,591,000USD156,833,000USD142,836,000USD124,538,000USD118,170,000USD133,882,000USD118,776,000USD
    Ebitda—154,497,000USD163,964,000USD149,885,000USD131,552,000USD125,100,000USD141,388,000USD126,294,000USD
    Depreciation And Amortization—6,906,000USD7,131,000USD7,049,000USD7,014,000USD6,930,000USD7,506,000USD7,518,000USD
    Reconciled Depreciation—6,906,000USD7,131,000USD7,049,000USD7,014,000USD6,930,000USD7,506,000USD7,518,000USD
    Selling And Marketing Expenses——————1,500,000USD—
    Interest Expense——————7,883,000USD7,528,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue2,530,234,000USD2,109,054,000USD1,885,842,000USD1,459,996,000USD1,142,377,000USD925,925,000USD860,969,000USD704,589,000USD
    Cost Of Revenue1,769,616,000USD1,452,749,000USD1,361,337,000USD1,027,558,000USD814,222,000USD647,199,000USD615,272,000USD489,059,000USD
    Gross Profit760,618,000USD656,305,000USD524,505,000USD432,438,000USD328,155,000USD278,726,000USD245,697,000USD215,530,000USD
    Selling General Administrative197,559,000USD178,684,000USD159,852,000USD130,100,000USD107,221,000USD91,456,000USD94,545,000USD75,681,000USD
    Unclassified Operating Expenses28,124,000USD29,251,000USD26,328,000USD22,341,000USD21,119,000USD19,528,000USD23,189,000USD38,001,000USD
    Total Operating Expenses225,683,000USD209,435,000USD187,680,000USD153,741,000USD129,540,000USD111,684,000USD118,434,000USD114,482,000USD
    Operating Income534,935,000USD446,870,000USD336,825,000USD278,697,000USD198,615,000USD167,042,000USD127,263,000USD101,048,000USD
    Net Interest Income12,780,000USD24,996,000USD-3,159,000USD-2,905,000USD-105,000USD307,000USD-1,568,000USD-8,157,000USD
    Income Before Tax542,377,000USD475,922,000USD335,682,000USD282,860,000USD201,852,000USD168,532,000USD124,832,000USD93,951,000USD
    Income Tax Expense91,254,000USD71,536,000USD52,872,000USD37,492,000USD20,004,000USD23,148,000USD24,389,000USD20,766,000USD
    Tax Provision91,254,000USD71,536,000USD45,438,000USD37,492,000USD20,004,000USD23,148,000USD24,389,000USD20,766,000USD
    Net Income451,123,000USD404,386,000USD282,810,000USD245,368,000USD181,848,000USD145,384,000USD100,443,000USD73,185,000USD
    Net Income From Continuing Ops451,123,000USD404,386,000USD273,182,000USD245,368,000USD181,848,000USD145,384,000USD100,443,000USD73,185,000USD
    Ebit542,377,000USD475,922,000USD336,170,000USD285,765,000USD201,957,000USD167,042,000USD127,263,000USD101,048,000USD
    Ebitda570,501,000USD505,173,000USD362,498,000USD308,106,000USD223,076,000USD186,570,000USD150,452,000USD139,849,000USD
    Depreciation And Amortization28,124,000USD29,251,000USD26,328,000USD22,341,000USD21,119,000USD19,528,000USD23,189,000USD38,801,000USD
    Reconciled Depreciation28,124,000USD29,251,000USD25,255,000USD22,341,000USD21,119,000USD19,528,000USD23,189,000USD38,801,000USD
    Total Other Income Expense Net7,442,000USD29,052,000USD-1,143,000USD4,163,000USD3,237,000USD1,490,000USD-2,431,000USD-7,097,000USD
    Selling And Marketing Expenses—1,500,000USD1,500,000USD1,300,000USD1,200,000USD700,000USD700,000USD800,000USD
    Interest Expense—24,996,000USD488,000USD2,905,000USD105,000USD307,000USD1,568,000USD8,157,000USD
    Non Operating Income Net Other———7,068,000USD3,342,000USD1,183,000USD-863,000USD1,060,000USD
    Net Income Applicable To Common Shares———245,368,000USD181,848,000USD145,384,000USD100,164,000USD72,894,000USD
    Interest Income——————1,568,000USD8,157,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets2,057,181,000USD2,129,613,000USD1,975,472,000USD1,753,012,000USD1,571,673,000USD1,897,369,000USD2,100,866,000USD2,084,061,000USD
    Cash And Equivalents502,688,000USD———————
    Total Current Assets1,050,285,000USD1,139,055,000USD989,624,000USD737,285,000USD520,805,000USD821,437,000USD1,029,229,000USD1,032,595,000USD
    Other Current Assets105,800,000USD91,793,000USD90,497,000USD78,900,000USD96,554,000USD81,784,000USD63,350,000USD64,229,000USD
    Other Non Current Assets25,196,000USD———————
    Total Liabilities1,623,320,000USD———————
    Total Current Liabilities1,435,429,000USD1,345,014,000USD1,343,748,000USD1,283,914,000USD1,220,443,000USD1,122,311,000USD1,104,553,000USD1,041,354,000USD
    Other Current Liabilities42,104,000USD———————
    Other Non Current Liabilities59,584,000USD———————
    Total Stockholder Equity433,861,000USD598,314,000USD459,071,000USD293,641,000USD172,351,000USD593,609,000USD825,545,000USD881,439,000USD
    Total Equity Including Noncontrolling Interest433,861,000USD———————
    Deferred Revenue904,722,000USD———————
    Property Plant Equipment Net282,963,000USD263,360,000USD248,870,000USD256,761,000USD264,985,000USD258,191,000USD252,264,000USD254,605,000USD
    Goodwill662,396,000USD———————
    Intangible Assets33,110,000USD33,265,000USD33,420,000USD33,657,000USD33,893,000USD34,130,000USD34,366,000USD34,727,000USD
    Accounts Payable37,527,000USD34,429,000USD28,142,000USD26,523,000USD43,275,000USD61,318,000USD32,528,000USD26,201,000USD
    Short Term Debt24,012,000USD23,838,000USD23,209,000USD24,906,000USD24,886,000USD23,689,000USD23,289,000USD23,616,000USD
    Common Stock279,000USD286,000USD284,000USD282,000USD281,000USD298,000USD306,000USD311,000USD
    Retained Earnings-511,368,000USD-336,111,000USD-459,981,000USD-596,237,000USD-703,215,000USD-269,716,000USD8,167,000USD65,636,000USD
    Accumulated Other Comprehensive Income-7,082,000USD-7,121,000USD-4,906,000USD-5,652,000USD-5,654,000USD-11,621,000USD-14,743,000USD-9,176,000USD
    Total Liab—1,531,299,000USD1,516,401,000USD1,459,371,000USD1,399,322,000USD1,303,760,000USD1,275,321,000USD1,202,622,000USD
    Other Current Liab—454,241,000USD438,007,000USD398,157,000USD343,499,000USD342,277,000USD361,440,000USD344,214,000USD
    Capital Stock—286,000USD284,000USD282,000USD281,000USD298,000USD306,000USD311,000USD
    Good Will—662,396,000USD662,396,000USD662,396,000USD662,396,000USD662,396,000USD662,396,000USD662,396,000USD
    Cash—652,681,000USD497,049,000USD285,351,000USD46,330,000USD441,436,000USD669,436,000USD656,900,000USD
    Cash And Short Term Investments—652,681,000USD497,049,000USD285,351,000USD46,330,000USD441,436,000USD669,436,000USD656,900,000USD
    Current Deferred Revenue—856,344,000USD854,390,000USD834,328,000USD808,783,000USD718,716,000USD710,585,000USD670,939,000USD
    Net Debt—-530,425,000USD-246,554,000USD-141,378,000USD103,502,000USD-314,776,000USD-543,202,000USD-528,623,000USD
    Short Long Term Debt Total—122,256,000USD250,495,000USD143,973,000USD149,832,000USD126,660,000USD126,234,000USD128,277,000USD
    Net Receivables—394,581,000USD402,078,000USD373,034,000USD377,921,000USD298,217,000USD296,443,000USD311,466,000USD
    Property Plant Equipment Gross—263,360,000USD372,142,000USD256,761,000USD264,985,000USD258,191,000USD351,133,000USD254,605,000USD
    Common Stock Shares Outstanding—28,962,000shares28,964,000shares29,710,000shares30,165,000shares31,196,000shares32,014,000shares32,088,000shares
    Non Current Assets Total—990,558,000USD985,848,000USD1,015,727,000USD1,050,868,000USD1,075,932,000USD1,071,637,000USD1,051,466,000USD
    Non Current Liabilities Total—186,285,000USD172,653,000USD175,457,000USD178,879,000USD181,449,000USD170,768,000USD161,268,000USD
    Non Current Liabilities Other—60,104,000USD57,655,000USD54,491,000USD51,917,000USD52,951,000USD42,734,000USD30,702,000USD
    Non Currrent Assets Other—28,317,000USD21,939,000USD25,724,000USD23,802,000USD21,523,000USD22,254,000USD23,055,000USD
    Net Working Capital—-205,959,000USD-354,124,000USD-546,629,000USD-699,638,000USD-300,874,000USD-75,324,000USD-8,759,000USD
    Unclassified Current Liabilities—-23,838,000USD———-23,689,000USD-23,289,000USD-23,616,000USD
    Unclassified Non Current Liabilities—126,181,000USD114,998,000USD120,966,000USD126,962,000USD128,498,000USD128,034,000USD130,566,000USD
    Unclassified Equity—940,974,000USD923,390,000USD894,966,000USD880,658,000USD874,350,000USD831,509,000USD824,357,000USD
    Unclassified Non Current Assets——19,223,000USD37,189,000USD65,792,000USD99,692,000USD100,357,000USD76,683,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets1,975,472,000USD2,100,866,000USD1,656,828,000USD1,352,495,000USD1,659,935,000USD1,390,677,000USD1,143,071,000USD967,933,000USD
    Intangible Assets33,420,000USD34,366,000USD35,809,000USD38,008,000USD41,360,000USD46,474,000USD54,350,000USD69,179,000USD
    Other Current Assets90,497,000USD63,350,000USD49,979,000USD52,293,000USD43,176,000USD34,923,000USD29,446,000USD21,383,000USD
    Total Liab1,516,401,000USD1,275,321,000USD1,097,878,000USD966,108,000USD707,007,000USD584,898,000USD416,788,000USD378,230,000USD
    Total Stockholder Equity459,071,000USD825,545,000USD558,950,000USD386,387,000USD952,928,000USD805,779,000USD726,283,000USD589,703,000USD
    Other Current Liab438,007,000USD338,151,000USD333,402,000USD257,672,000USD186,898,000USD157,894,000USD128,239,000USD4,861,000USD
    Common Stock284,000USD306,000USD308,000USD309,000USD360,000USD355,000USD360,000USD356,000USD
    Capital Stock284,000USD306,000USD308,000USD309,000USD360,000USD355,000USD360,000USD356,000USD
    Retained Earnings-459,981,000USD8,167,000USD-221,645,000USD-359,827,000USD234,984,000USD115,229,000USD68,109,000USD-41,487,000USD
    Good Will662,396,000USD662,396,000USD662,396,000USD662,396,000USD662,396,000USD662,396,000USD662,396,000USD660,981,000USD
    Cash497,049,000USD669,436,000USD245,449,000USD28,265,000USD461,304,000USD277,766,000USD131,920,000USD23,275,000USD
    Cash And Short Term Investments497,049,000USD669,436,000USD245,449,000USD28,265,000USD461,304,000USD277,766,000USD131,920,000USD23,275,000USD
    Total Current Assets989,624,000USD1,029,229,000USD593,828,000USD333,962,000USD690,912,000USD473,651,000USD317,028,000USD178,114,000USD
    Total Current Liabilities1,343,748,000USD1,104,553,000USD925,131,000USD803,470,000USD557,217,000USD440,110,000USD343,002,000USD257,026,000USD
    Current Deferred Revenue854,390,000USD710,585,000USD559,860,000USD462,729,000USD344,641,000USD255,664,000USD192,359,000USD147,935,000USD
    Net Debt-246,554,000USD-519,913,000USD-103,327,000USD160,602,000USD-330,339,000USD-162,623,000USD-86,708,000USD56,446,000USD
    Short Term Debt23,209,000USD23,289,000USD292,961,000USD50,000,000USD159,286,000USD134,367,000USD109,252,000USD87,493,000USD
    Short Long Term Debt Total250,495,000USD149,523,000USD142,122,000USD188,867,000USD130,965,000USD115,143,000USD45,212,000USD191,698,000USD
    Net Receivables402,078,000USD296,443,000USD298,400,000USD253,404,000USD186,432,000USD160,962,000USD155,662,000USD133,449,000USD
    Accounts Payable28,142,000USD32,528,000USD31,869,000USD33,069,000USD25,678,000USD26,552,000USD22,404,000USD16,737,000USD
    Property Plant Equipment Net248,870,000USD252,264,000USD265,390,000USD248,917,000USD222,711,000USD198,826,000USD99,444,000USD52,255,000USD
    Property Plant Equipment Gross372,142,000USD351,133,000USD344,794,000USD248,917,000USD222,711,000USD198,826,000USD99,444,000USD52,255,000USD
    Accumulated Other Comprehensive Income-4,906,000USD-14,743,000USD-10,072,000USD-12,392,000USD-4,846,000USD-131,000USD-2,741,000USD-2,517,000USD
    Common Stock Shares Outstanding29,527,000shares32,014,000shares31,841,000shares33,671,000shares37,697,000shares37,708,000shares37,576,000shares36,912,000shares
    Non Current Assets Total985,848,000USD1,071,637,000USD1,063,000,000USD1,018,533,000USD969,023,000USD917,026,000USD826,043,000USD789,819,000USD
    Non Current Liabilities Total172,653,000USD170,768,000USD172,747,000USD162,638,000USD149,790,000USD144,788,000USD73,786,000USD121,204,000USD
    Non Current Liabilities Other57,655,000USD42,734,000USD28,221,000USD22,701,000USD148,710,000USD131,237,000USD15,725,000USD37,288,000USD
    Non Currrent Assets Other21,939,000USD22,254,000USD24,970,000USD21,129,000USD17,422,000USD8,794,000USD9,477,000USD6,691,000USD
    Net Working Capital-354,124,000USD-75,324,000USD-331,303,000USD-469,508,000USD133,695,000USD33,541,000USD-25,974,000USD-78,912,000USD
    Unclassified Non Current Assets19,223,000USD100,357,000USD74,435,000USD-21,129,000USD-17,422,000USD-122,603,000USD-9,477,000USD—
    Unclassified Non Current Liabilities114,998,000USD128,034,000USD144,526,000USD115,096,000USD-18,825,000USD-29,645,000USD16,638,000USD-13,704,000USD
    Unclassified Equity923,390,000USD831,509,000USD790,051,000USD770,485,000USD727,497,000USD695,549,000USD666,225,000USD639,025,000USD
    Inventory——1USD———1USD7,000USD
    Unclassified Current Liabilities——-292,961,000USD-50,000,000USD-159,286,000USD-134,367,000USD-109,252,000USD—
    Deferred Long Term Liab———1,070,000USD1,080,000USD13,551,000USD12,849,000USD900,000USD
    Other Liab———23,771,000USD18,825,000USD29,645,000USD28,574,000USD16,999,000USD
    Other Assets———69,212,000USD42,556,000USD123,139,000USD9,853,000USD7,404,000USD
    Short Long Term Debt———50,000,000USD————
    Treasury Stock———-12,497,000USD-5,427,000USD-5,578,000USD-6,030,000USD-6,030,000USD
    Net Tangible Assets———-314,017,000USD249,172,000USD96,909,000USD9,537,000USD-140,457,000USD
    Long Term Debt———————79,721,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation13,616,000USD
    Stock Based Compensation9,266,000USD
    Deferred Income Tax22,824,000USD
    Other Non Cash Items-255,000USD
    Change To Liabilities43,672,000USD
    Change In Working Capital-15,994,000USD
    Operating Cash Flow313,799,000USD
    Capital Expenditures-30,725,000USD
    Other Investing Activities-92,000USD
    Unclassified Investing Cash Flow184,000USD
    Investing Cash Flow-30,633,000USD
    Net Common Stock Issuance-294,764,000USD
    Unclassified Financing Cash Flow19,094,000USD
    Financing Cash Flow-275,670,000USD
    Effect Of Forex Changes On Cash-1,857,000USD
    Change In Cash5,639,000USD
    End Cash Flow502,688,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income123,870,000USD135,133,000USD111,135,000USD90,260,000USD114,595,000USD117,018,000USD96,426,000USD88,351,000USD
    Depreciation6,906,000USD7,131,000USD6,340,000USD7,014,000USD6,930,000USD7,506,000USD7,518,000USD7,235,000USD
    Stock Based Compensation4,918,000USD5,620,000USD6,323,000USD5,951,000USD16,892,000USD5,889,000USD11,727,000USD3,588,000USD
    Other Non Cash Items6,249,000USD5,243,000USD6,438,000USD5,605,000USD5,562,000USD5,646,000USD5,911,000USD6,092,000USD
    Change To Account Receivables7,822,000USD-29,096,000USD4,861,000USD-79,911,000USD-2,069,000USD15,274,000USD-10,318,000USD-21,830,000USD
    Change In Working Capital-8,698,000USD22,118,000USD87,463,000USD5,589,000USD-18,892,000USD78,806,000USD29,007,000USD11,185,000USD
    Total Cash From Operating Activities151,788,000USD192,652,000USD246,209,000USD148,526,000USD125,836,000USD190,666,000USD149,075,000USD116,397,000USD
    Capital Expenditures-6,814,000USD-4,536,000USD16,107,000USD-6,113,000USD-9,994,000USD-7,643,000USD-10,537,000USD-12,871,000USD
    Free Cash Flow144,974,000USD188,116,000USD262,316,000USD142,413,000USD115,842,000USD183,023,000USD138,538,000USD103,526,000USD
    Total Cashflows From Investing Activities-6,748,000USD-4,473,000USD-10,660,000USD-6,020,000USD-9,987,000USD-7,562,000USD-10,486,000USD-12,790,000USD
    Total Cash From Financing Activities12,670,000USD22,729,000USD3,413,000USD-540,564,000USD-345,966,000USD-168,609,000USD6,274,000USD666,000USD
    Sale Purchase Of Stock0USD0USD-4,574,000USD-540,915,000USD-371,900,000USD-169,867,000USD0USD0USD
    Change In Cash155,632,000USD211,698,000USD239,021,000USD-395,106,000USD-228,000,000USD12,536,000USD146,006,000USD103,884,000USD
    Begin Period Cash Flow497,049,000USD285,351,000USD46,330,000USD441,436,000USD669,436,000USD656,900,000USD510,894,000USD407,010,000USD
    End Period Cash Flow652,681,000USD497,049,000USD285,351,000USD46,330,000USD441,436,000USD669,436,000USD656,900,000USD510,894,000USD
    Other Cashflows From Investing Activities66,000USD63,000USD-26,767,000USD93,000USD7,000USD81,000USD51,000USD81,000USD
    Other Cashflows From Financing Activities12,670,000USD—7,987,000USD351,000USD25,934,000USD1,258,000USD6,274,000USD666,000USD
    Unclassified Operating Cash Flow18,543,000USD17,407,000USD28,510,000USD34,107,000USD—-24,199,000USD-1,514,000USD—
    Unclassified Financing Cash Flow—22,729,000USD——————
    Investments——-10,660,000USD-6,020,000USD-9,987,000USD-7,562,000USD-10,486,000USD-12,790,000USD
    Unclassified Investing Cash Flow——10,660,000USD6,020,000USD9,987,000USD7,562,000USD10,486,000USD12,790,000USD
    Net Borrowings—————0USD0USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income451,123,000USD404,386,000USD282,810,000USD245,368,000USD181,848,000USD145,384,000USD100,443,000USD73,185,000USD
    Depreciation27,178,000USD29,251,000USD26,328,000USD22,341,000USD21,119,000USD19,528,000USD23,189,000USD38,801,000USD
    Stock Based Compensation34,786,000USD25,514,000USD20,516,000USD21,412,000USD14,469,000USD13,784,000USD20,741,000USD6,499,000USD
    Other Non Cash Items23,085,000USD19,115,000USD22,351,000USD15,888,000USD16,296,000USD13,196,000USD11,856,000USD-5,444,000USD
    Change To Account Receivables-106,215,000USD2,242,000USD-48,282,000USD-66,920,000USD-24,982,000USD-5,530,000USD-21,256,000USD-27,047,000USD
    Change In Working Capital96,278,000USD157,181,000USD106,486,000USD106,055,000USD66,707,000USD66,257,000USD35,588,000USD39,601,000USD
    Total Cash From Operating Activities713,223,000USD608,815,000USD433,374,000USD388,050,000USD263,327,000USD258,676,000USD201,867,000USD156,584,000USD
    Capital Expenditures-31,356,000USD-36,548,000USD-36,648,000USD-36,879,000USD-28,271,000USD-31,340,000USD-17,912,000USD-16,024,000USD
    Free Cash Flow681,867,000USD572,267,000USD396,726,000USD351,171,000USD235,056,000USD227,336,000USD183,955,000USD140,560,000USD
    Total Cashflows From Investing Activities-31,140,000USD-28,308,000USD-34,629,000USD-38,742,000USD-31,364,000USD-31,214,000USD-19,144,000USD-16,973,000USD
    Net Borrowings0USD0USD-50,000,000USD50,000,000USD50,000,000USD50,000,000USD-80,438,000USD-144,069,000USD
    Total Cash From Financing Activities-860,388,000USD-154,009,000USD-182,642,000USD-775,775,000USD-44,453,000USD-82,282,000USD-73,918,000USD-141,580,000USD
    Sale Purchase Of Stock-917,389,000USD-169,867,000USD-144,020,000USD-847,849,000USD-62,096,000USD-98,274,000USD6,520,000USD2,489,000USD
    Change In Cash-172,387,000USD423,987,000USD217,184,000USD-433,039,000USD183,538,000USD145,846,000USD108,638,000USD-3,210,000USD
    Begin Period Cash Flow669,436,000USD245,449,000USD28,265,000USD461,304,000USD277,766,000USD131,920,000USD23,282,000USD26,492,000USD
    End Period Cash Flow497,049,000USD669,436,000USD245,449,000USD28,265,000USD461,304,000USD277,766,000USD131,920,000USD23,282,000USD
    Other Cashflows From Investing Activities216,000USD8,240,000USD2,019,000USD-1,863,000USD-3,093,000USD126,000USD-1,232,000USD-949,000USD
    Other Cashflows From Financing Activities-860,388,000USD15,858,000USD11,378,000USD22,074,000USD17,643,000USD15,992,000USD6,520,000USD608,000USD
    Unclassified Operating Cash Flow80,773,000USD-26,632,000USD-25,117,000USD-23,014,000USD-37,112,000USD—10,050,000USD3,942,000USD
    Unclassified Financing Cash Flow917,389,000USD—11,378,000USD22,074,000USD-50,000,000USD-50,000,000USD-6,520,000USD—
    Investments—-28,308,000USD-35,852,000USD-38,742,000USD-31,364,000USD-31,214,000USD-19,144,000USD-16,973,000USD
    Unclassified Investing Cash Flow—28,308,000USD35,852,000USD38,742,000USD31,364,000USD31,214,000USD19,144,000USD16,973,000USD
    Change To Inventory——66,193,000USD—24,982,000USD5,530,000USD21,256,000USD27,788,000USD
    Dividends Paid——-11,378,000USD-22,074,000USD————
    Change To Liabilities———58,907,000USD28,022,000USD21,634,000USD26,554,000USD30,371,000USD
    Cash And Cash Equivalents Changes———-426,467,000USD187,510,000USD145,180,000USD108,805,000USD-1,969,000USD
    Issuance Of Capital Stock———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductAntiviral And Anti Infective37,773,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductCardiology59,982,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductCentral Nervous System82,858,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductMetabolic219,067,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOncology209,372,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOther98,279,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductAntiviral And Anti Infective38,021,000USD0001668397-26-000019
    Q1 2026Quarterly · 2026-03-31ProductCardiology56,261,000USD0001668397-26-000019
    Q1 2026Quarterly · 2026-03-31ProductCentral Nervous System80,207,000USD0001668397-26-000019
    Q1 2026Quarterly · 2026-03-31ProductMetabolic237,558,000USD0001668397-26-000019
    Q1 2026Quarterly · 2026-03-31ProductOncology201,239,000USD0001668397-26-000019
    Q1 2026Quarterly · 2026-03-31ProductOther93,318,000USD0001668397-26-000019
    Q4 2025Quarterly · 2025-12-31ProductAntiviral And Anti Infective38,250,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductCardiology63,038,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductCentral Nervous System73,181,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductMetabolic249,813,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOncology195,916,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther88,252,000USDLegacy provider
    FY 2025Yearly · 2025-12-31ProductAntiviral And Anti Infective134,935,000USD0001668397-26-000006
    FY 2025Yearly · 2025-12-31ProductCardiology239,371,000USD0001668397-26-000006
    FY 2025Yearly · 2025-12-31ProductCentral Nervous System254,838,000USD0001668397-26-000006
    FY 2025Yearly · 2025-12-31ProductMetabolic744,957,000USD0001668397-26-000006
    FY 2025Yearly · 2025-12-31ProductOncology747,585,000USD0001668397-26-000006
    FY 2025Yearly · 2025-12-31ProductOther408,548,000USD0001668397-26-000006
    Q3 2025Quarterly · 2025-09-30ProductAntiviral And Anti Infective36,517,000USD0001668397-25-000110
    Q3 2025Quarterly · 2025-09-30ProductCardiology59,470,000USD0001668397-25-000110
    Q3 2025Quarterly · 2025-09-30ProductCentral Nervous System65,627,000USD0001668397-25-000110
    Q3 2025Quarterly · 2025-09-30ProductMetabolic199,256,000USD0001668397-25-000110
    Q3 2025Quarterly · 2025-09-30ProductOncology192,635,000USD0001668397-25-000110
    Q3 2025Quarterly · 2025-09-30ProductOther106,398,000USD0001668397-25-000110
    Q2 2025Quarterly · 2025-06-30ProductAntiviral And Anti Infective29,105,000USD0001668397-25-000087
    Q2 2025Quarterly · 2025-06-30ProductCardiology58,584,000USD0001668397-25-000087
    Q2 2025Quarterly · 2025-06-30ProductCentral Nervous System61,129,000USD0001668397-25-000087
    Q2 2025Quarterly · 2025-06-30ProductMetabolic147,873,000USD0001668397-25-000087
    Q2 2025Quarterly · 2025-06-30ProductOncology188,558,000USD0001668397-25-000087
    Q2 2025Quarterly · 2025-06-30ProductOther118,062,000USD0001668397-25-000087
    Q1 2025Quarterly · 2025-03-31ProductAntiviral And Anti Infective31,063,000USD0001668397-26-000019
    Q1 2025Quarterly · 2025-03-31ProductCardiology58,279,000USD0001668397-26-000019
    Q1 2025Quarterly · 2025-03-31ProductCentral Nervous System54,901,000USD0001668397-26-000019
    Q1 2025Quarterly · 2025-03-31ProductMetabolic148,015,000USD0001668397-26-000019
    Q1 2025Quarterly · 2025-03-31ProductOncology170,476,000USD0001668397-26-000019
    Q1 2025Quarterly · 2025-03-31ProductOther95,836,000USD0001668397-26-000019
    Q4 2024Quarterly · 2024-12-31ProductAntiviral And Anti Infective34,842,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductCardiology58,304,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductCentral Nervous System49,224,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductMetabolic122,868,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductOncology168,170,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductOther103,181,000USDLegacy provider
    FY 2024Yearly · 2024-12-31ProductAntiviral And Anti Infective156,460,000USD0001668397-26-000006
    FY 2024Yearly · 2024-12-31ProductCardiology230,454,000USD0001668397-26-000006
    FY 2024Yearly · 2024-12-31ProductCentral Nervous System181,977,000USD0001668397-26-000006
    FY 2024Yearly · 2024-12-31ProductMetabolic457,542,000USD0001668397-26-000006
    FY 2024Yearly · 2024-12-31ProductOncology651,237,000USD0001668397-26-000006
    FY 2024Yearly · 2024-12-31ProductOther431,384,000USD0001668397-26-000006
    Q3 2024Quarterly · 2024-09-30ProductAntiviral And Anti Infective38,384,000USD0001668397-25-000110
    Q3 2024Quarterly · 2024-09-30ProductCardiology55,814,000USD0001668397-25-000110
    Q3 2024Quarterly · 2024-09-30ProductCentral Nervous System42,098,000USD0001668397-25-000110
    Q3 2024Quarterly · 2024-09-30ProductMetabolic124,733,000USD0001668397-25-000110
    Q3 2024Quarterly · 2024-09-30ProductOncology164,917,000USD0001668397-25-000110
    Q3 2024Quarterly · 2024-09-30ProductOther107,371,000USD0001668397-25-000110
    FY 2023Yearly · 2023-12-31ProductAntiviral And Anti Infective163,312,000USD0001668397-26-000006
    FY 2023Yearly · 2023-12-31ProductCardiology193,690,000USD0001668397-26-000006
    FY 2023Yearly · 2023-12-31ProductCentral Nervous System160,057,000USD0001668397-26-000006
    FY 2023Yearly · 2023-12-31ProductMetabolic376,842,000USD0001668397-26-000006
    FY 2023Yearly · 2023-12-31ProductOncology587,097,000USD0001668397-26-000006
    FY 2023Yearly · 2023-12-31ProductOther404,844,000USD0001668397-26-000006
    FY 2022Yearly · 2022-12-31ProductAntiviral And Anti Infective118,031,000USD0001668397-25-000017
    FY 2022Yearly · 2022-12-31ProductCardiology174,634,000USD0001668397-25-000017
    FY 2022Yearly · 2022-12-31ProductCentral Nervous System157,939,000USD0001668397-25-000017
    FY 2022Yearly · 2022-12-31ProductMetabolic244,682,000USD0001668397-25-000017
    FY 2022Yearly · 2022-12-31ProductOncology467,796,000USD0001668397-25-000017
    FY 2022Yearly · 2022-12-31ProductOther296,914,000USD0001668397-25-000017
    FY 2021Yearly · 2021-12-31ProductRevenue Net — Antiviral And Anti Infective110,976,000USD0001668397-24-000013
    FY 2021Yearly · 2021-12-31ProductRevenue Net — Cardiology119,692,000USD0001668397-24-000013
    FY 2021Yearly · 2021-12-31ProductRevenue Net — Central Nervous System121,548,000USD0001668397-24-000013
    FY 2021Yearly · 2021-12-31ProductRevenue Net — Metabolic159,900,000USD0001668397-24-000013
    FY 2021Yearly · 2021-12-31ProductRevenue Net — Oncology362,846,000USD0001668397-24-000013
    FY 2021Yearly · 2021-12-31ProductRevenue Net — Other267,415,000USD0001668397-24-000013
    FY 2020Yearly · 2020-12-31ProductRevenue Net — Antiviral And Anti Infective103,259,000USD0001668397-23-000008
    FY 2020Yearly · 2020-12-31ProductRevenue Net — Cardiology95,153,000USD0001668397-23-000008
    FY 2020Yearly · 2020-12-31ProductRevenue Net — Central Nervous System88,393,000USD0001668397-23-000008
    FY 2020Yearly · 2020-12-31ProductRevenue Net — Metabolic126,075,000USD0001668397-23-000008
    FY 2020Yearly · 2020-12-31ProductRevenue Net — Oncology297,675,000USD0001668397-23-000008
    FY 2020Yearly · 2020-12-31ProductRevenue Net — Other215,370,000USD0001668397-23-000008
    FY 2019Yearly · 2019-12-31ProductDirect Revenue0USD0001564590-20-006385
    FY 2019Yearly · 2019-12-31ProductReimbursed Out Of Pocket Revenue0USD0001564590-20-006385
    FY 2019Yearly · 2019-12-31ProductRevenue Net — Antiviral And Anti Infective86,390,000USD0001564590-20-006385
    FY 2019Yearly · 2019-12-31ProductRevenue Net — Cardiology91,258,000USD0001564590-20-006385
    FY 2019Yearly · 2019-12-31ProductRevenue Net — Central Nervous System65,391,000USD0001564590-20-006385
    FY 2019Yearly · 2019-12-31ProductRevenue Net — Metabolic138,650,000USD0001564590-20-006385
    FY 2019Yearly · 2019-12-31ProductRevenue Net — Oncology256,766,000USD0001564590-20-006385
    FY 2019Yearly · 2019-12-31ProductRevenue Net — Other222,514,000USD0001564590-20-006385
    FY 2018Yearly · 2018-12-31ProductDirect Revenue0USD0001564590-19-004451
    FY 2018Yearly · 2018-12-31ProductReimbursed Out Of Pocket Revenue0USD0001564590-19-004451
    FY 2018Yearly · 2018-12-31ProductRevenue Net — Antiviral And Anti Infective76,739,000USD0001564590-19-004451
    FY 2018Yearly · 2018-12-31ProductRevenue Net — Cardiology91,824,000USD0001564590-19-004451
    FY 2018Yearly · 2018-12-31ProductRevenue Net — Central Nervous System53,904,000USD0001564590-19-004451
    FY 2018Yearly · 2018-12-31ProductRevenue Net — Endocrine26,002,000USD0001564590-19-004451
    FY 2018Yearly · 2018-12-31ProductRevenue Net — Medical Devices11,772,000USD0001564590-19-004451
    FY 2018Yearly · 2018-12-31ProductRevenue Net — Metabolic94,128,000USD0001564590-19-004451

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.